

Press Release

12 May 2022 12:00:00 CEST

2cureX AB nominates Dr. Michael Schaefer to the Board of Directors

Dr. Michael Schaefer has been proposed as new member of the Board of Directors of 2cureX AB. His experience in oncology, lab automation and Asian markets will be of great value at this stage of the company expansion.

Dr. Schaefer is biologist and chemist by Mainz University (Germany). His professional career started at E. Merck Darmstadt, in Microbiology and Cell Diagnostics. He moved to Bayer Diagnostics as Marketing Director for Haematology and Lab Information Systems, leading the company to a top position in the market. Appointed Regional Director in South-East Asia in 1993, based in Singapore, he grew the turnover of the company by a factor of five in the following four years.

He joined Sysmex Corporation in 1997 to lead the operations in EMEA, bringing the company over the following twenty years to the European market leader position in lab haematology, coagulation and urinalysis, with sales of about half a billion EUR. In the process, he established and was Director of most of the close to thirty Sysmex affiliates in EMEA.

In his last years at Sysmex he was appointed Executive VP of Sysmex Corporation, Kobe, Japan, in charge of New Business Development, where he led three major acquisition projects and defined the company Global strategy in the Oncology area.

Povl-André Bendz, Chairman of the Board at 2cureX AB: “We are very pleased that Dr. Schaefer agreed to be nominated to our Board of Directors. His experience in oncology, lab automation and Asian markets fits very well to the current expansion of 2cureX, and we are looking forward to the outcome of the Annual General Meeting to welcome him on board.

At the same time, I would like to thank Jørgen Drejer, who has requested to step down as a member of the Board, for his contribution since he joined five years ago. The company has greatly benefitted from his experience and insights in the transition from the pre-IPO stage to being a listed company”.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The portfolio of IndiTreat® tests is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® mCRC Start for first line of therapy, IndiTreat® mCRC Extend and IndiTreat® mCRC Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

[2cureX AB nominates Dr. Michael Schaefer to the Board of Directors](#)